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Abstract. PURPOSE: To determine whether FOLFOX4 (infusional ﬂu-
orouracil, leucovorin, and oxaliplatin) administered as palliative che-
motherapy to patients with advanced hepatocellular carcinoma
(HCC) provides a survival beneﬁt and efﬁcacy versus doxorubicin.
PATIENTS AND METHODS: This multicenter, open-label, random-
ized, phase III study in mainland China, Taiwan, Korea, and Thailand
involved 371 patients age 18 to 75 years who had locally advanced
or metastatic HCC and were ineligible for curative resection or local
treatment. They were randomly assigned at a ratio of one to one to
receive either FOLFOX4 (n = 184) or doxorubicin (n = 187). The pri-
mary end point was overall survival (OS); secondary end points
included progression-free survival (PFS), response rate (RR) by
RECIST (version 1.0), and safety.
RESULTS: At the prespeciﬁed ﬁnal analysis, median OS was
6.40 months with FOLFOX4 (95% CI, 5.30 to 7.03) and 4.97 months
with doxorubicin (95% CI, 4.23 to 6.03; P = .07; hazard ratio [HR],
0.80; 95% CI, 0.63 to 1.02). Median PFS was 2.93 months with FOL-
FOX4 (95% CI, 2.43 to 3.53), and 1.77 months with doxorubicin
(95% CI, 1.63 to 2.30; P < .001; HR, 0.62; 95% CI, 0.49 to 0.79). RR
was 8.15% with FOLFOX4 and 2.67% with doxorubicin (P = .02). On
continued follow-up, the trend toward increased OS with FOLFOX4
was maintained (P = .04; HR, 0.79; 95% CI, 0.63 to 0.99). Toxicity
was consistent with previous experiences with FOLFOX4; proportions
of grade 3 to 4 adverse events were similar between treatments.
CONCLUSION: Although the study did not meet its primary end
point, the trend toward improved OS with FOLFOX4, along with
increased PFS and RR, suggests that this regimen may confer some
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Systemic therapyof hepatocellular carcinoma (HCC) has had a long
track of disappointing results until the advent of sorafenib. This
multikinase inhibitor delayed tumor progression and improved
survival in two randomized placebo controlled trials that included
all types of populations in terms of baseline characteristics and
underlying liver disease [1,2]. Thus, it is currently the sole agent
approved for the systemic treatment of HCC. However, the avail-
ability of an effective option does not deny the need to further
investigate novel agents in order to further improve the survival
of patients with advanced HCC. While major effort is placed in
the development of targeted agents, several authors have focused
on the potential usefulness of conventional chemotherapy. The
common approach in both instances is to test the new agent in
combination with sorafenib, or in second line vs. placebo. Qin
et al. [3] did not adhere to this approach as their phase 3 trial test-
ing FOLFOX-4 (infusional ﬂuorouracil, leucovorin, and oxaliplatin)
vs. doxorubicin in patientswith advancedHCCwas began immedi-
ately after the sorafenib success and its designmaintained despite
sorafenib ofﬁcial approval at a later time. The study was run in
China, Taiwan, Korea, and Thailand and recruited 371 patients
with HCC (80% BCLC C). The primary end-point of the study
was overall survival and the design included interim analysis at
a given number of deaths applying the O’Brien Fleming alpha
spending rule. The survival ﬁgures at each interim analysis are
meaningful to expose why such rules are in place and why a
reduced sample size may provide unreliable results due to several
factors, but mostly due to imbalance between treatment arms.
Indeed, the patients were not stratiﬁed prior to randomization
according to any of the usual variables: BCLC stage, AFP concentra-
tion, etiology. Thereby, the survival analysiswas promising at each
interim analysis to ultimately fail at trial closure. This negative
outcome is the unequivocal result of the study.
Nevertheless, the authors looked at secondary end-points and
observed that progression free survival (PFS) was improved, and
when they extended the follow-up beyond trial closure, the
survival difference turned signiﬁcantly different. These ﬁndings
have been presented as suggestive of a potential beneﬁt
and endorsing FOLFOX-4 as a valuable approach to pursue.
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Table 1. Survival of patients with HCC treated by systemic agents in phase 3 trials in 1st and 2nd line.
Study, [Ref.] Year Drug n OS (mo) p value Hazard ratio (95% CI)
First line
Llovet et al., [1] 2008 Sorafenib vs. placebo 299/303 10.7 vs. 7.9 <0.001 0.69 (0.55-0.87)
Cheng et al., [2] 2009 Sorafenib vs. placebo 150/76 6.5 vs. 4.2 0.01 0.68 (0.50-0.93)
Zhu et al., [6] 2012 Sorafenib + erlotinib vs.
sorafenib + placebo
362/358 9.5 vs. 8.5 n.s. 0.92 (0.78-1.11)
Cainap et al., [7] 2012 Linifanib vs. sorafenib 514/521 9.1 vs. 9.8 n.s. 1.04 (0.89-1.22)
Cheng et al., [4] 2013 Sunitinib vs. sorafenib 530/544 7.9 vs. 10.2 n.s. 1.30 (1.13-1.50)
Johnson et al., [8] 2013 Brivanib vs. sorafenib 577/578 9.5 vs. 9.9 n.s. 1.07 (0.94-1.23)
Qin et al., [3] 2013 FOLFOX-4 vs. doxorubicin 184/187 6.4 vs. 4.9 n.s. 0.80 (0.63-1.02)
Second line
Llovet et al., [9] 2013 Brivanib vs. placebo 263/132 9.4 vs. 8.2 n.s. 0.89 (0.69-1.15)
Zhu et al., [10] 2014 Everolimus vs. placebo 362/184 7.6 vs. 7.3 n.s. 1.05 (0.86-1.27)
n.s., not signiﬁcant. (See above-mentioned references for further information.)
JOURNAL OF HEPATOLOGYUnfortunately, there is no scientiﬁc strength in this wishful
thinking. PFS has never been shown to be a surrogate of overall
survival in patients with HCC and there are now data showing
that PFS may be different but survival is not when testing drugs
such as sunitinib [4]. Furthermore, the survival data beyond trial
closure is an allowance for major biases including the potential
treatment of surviving patients with sorafenib either after
approval in each country or as an off label indication as the drug
was already available for renal cell cancer patients. It could be
argued that this event would affect equally both arms, but this
needs to be proven.
The authors state that the survival data are encouraging as
they compare well with those in the sorafenib vs. placebo trial
that was run in the same geographic region. It is not correct to
compare survival across trials when the selection of patients is
not homogeneous and even more if the trial design is different.
Patients may easily accept to enter trials with all arms providing
active therapy, while entering a placebo controlled trial would be
delayed until no other option would be feasible. Indeed, the anal-
ysis of the recent trials with two active arms in HCC patients
shows that the survival data are not so dismal, even if recruiting
mostly in Asia (Table 1). This poor survival opens the possibility
of patient’s survival being impaired by drugs with potential
adverse events such as Hepatitis B virus reactivation. This is a
major complication when using chemotherapy and nothing is
mentioned in the trial about the use of antivirals and virus repli-
cation. A placebo control arm would have avoided this issue but
the authors used doxorubicin as they assumed that this was the
de facto control arm for trials in patients with HCC. Absence of
proven efﬁcacy explains why doxorubicin is not an approved
HCC treatment and this is why it was not used for the control
arm in the sorafenib trials. This likely contributed to the accep-
tance of the survival beneﬁts: if doxorubicin would have been
used as control, some could have argued that the difference could
have been due to increased mortality due to doxorubicin toxicity
as might be raised in the study by Qin et al. [3].
Despite all these critical concerns, the Chinese practice guide-
lines have accepted FOLFOX-4 as a valid treatment for patients
with advanced HCC [5]. Contrarily, Western guidelines would
require a robust proof of survival beneﬁt to do so. This exposes
the need to prime an active scientiﬁc exchange between EastJournal of Hepatology 201and West so that the same degree of scientiﬁc strength is
requested worldwide to inform practice guidelines to facilitate
evidence based practice of medicine.Conﬂict of interest
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